{
    "Trade/Device Name(s)": [
        "Audit\u00ae MicroControls\u2122 Linearity LQ Special Diabetes",
        "Audit Microcontrols Linearity LQ Special Diabetes",
        "Audit\u00ae MicroControls\u2122M Linearity LQ Special Diabetes"
    ],
    "Submitter Information": "Aalto Scientific, Ltd.",
    "510(k) Number": "K142978",
    "Predicate Device Reference 510(k) Number(s)": [
        "K130157"
    ],
    "Regulatory Class": "Class I, Reserved",
    "Product Code(s)": [
        "JJY"
    ],
    "Summary Letter Date": "October 15, 2014",
    "Summary Letter Received Date": "October 17, 2014",
    "Submission Date": "November 18, 2014",
    "Regulation Number(s)": [
        "21CFR862.1660"
    ],
    "Regulation Name(s)": [
        "Quality control material (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "Fructosamine",
        "Insulin",
        "C-peptide"
    ],
    "Specimen Type(s)": [
        "Human serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Roche Modular P",
        "Roche Cobas e411"
    ],
    "Method(s)/Technology(ies)": [
        "Assayed quality control material"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Quality control material",
        "Linearity set"
    ],
    "Document Summary": "FDA 510(k) summary for Audit MicroControls Linearity LQ Special Diabetes, an assayed control material for linearity and calibration verification of fructosamine, insulin, and C-peptide assays",
    "Indications for Use Summary": "Intended to simulate human patient samples for use in determining linearity, calibration verification, and verification of reportable range for fructosamine, insulin, and C-peptide; for In Vitro Diagnostic use only",
    "fda_folder": "Clinical Chemistry"
}